

Vincent Charlon joins Anergis as Chief Executive Officer (CEO);  
Christophe Reymond becomes Chief Scientific Officer (CSO).

Vincent Charlon brings twenty years of clinical development experience in various indications with Hoffmann-La Roche (1990-1998, US and Switzerland) and Hesperion (1998-2006 Switzerland, Europe, Israel and US). Vincent Charlon was CEO of the start-up drug repositioning company LS Pharma International (2007-2008) before joining Anergis.

Christophe Reymond remains responsible for all scientific and research activities of Anergis, based on his long-standing scientific experience in particular with Dictagene SA (1991-2005) and since joining Anergis (2005-present).